Trials / Not Yet Recruiting
Not Yet RecruitingNCT05909137
Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Feasibility of Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- Xinqiao Hospital of Chongqing · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
Simultaneous radiotherapy followed by adjuvant immunotherapy is the standard treatment modality of unresectable stage III NSCLC. Our preliminary study confirmed that the treatment of CTV-omitted IMRT regimen did not compromise the PFS or OS and significantly reduced the incidence of severe radiation pneumonia and radiation esophagitis. The purpose of this study was to observe the role of radiotherapy modalities that omit CTV in the context of immunotherapy for NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | IMRT+adjuvant immunotherapy | The enrollment was randomly (1:1) assigned into the study group with CTV-omitted IMRT and the control group with CTV-delineated IMRT using a random number table. |
Timeline
- Start date
- 2026-02-01
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2023-06-18
- Last updated
- 2025-07-14
Source: ClinicalTrials.gov record NCT05909137. Inclusion in this directory is not an endorsement.